Nattokinase — Benefits Deep Dive

Nattokinase is a 275-amino-acid fibrinolytic serine protease isolated from natto, the traditional Japanese fermented soybean food. Discovered by Dr. Hiroyuki Sumi at the University of Chicago in 1987 while screening over 200 foods for fibrinolytic activity, the enzyme is unusual in two respects: it acts directly on fibrin (the structural protein of blood clots) rather than indirectly through plasminogen activation as tissue plasminogen activator (tPA) does, and it appears to retain measurable activity after oral absorption — one of the few proteolytic enzymes for which this is documented in human pharmacokinetic studies. The standard clinical dose is 2,000 fibrinolytic units (FU) per day, the threshold used in most positive trials. Four benefit pages below explore the conditions where nattokinase produces the largest clinical effect — cardiovascular fibrinolysis and venous thromboembolism prevention, modest-but-meaningful blood pressure reduction, atherosclerosis and stroke prevention (including the honest treatment of the post-COVID spike-protein-fibrin controversy and the Japanese longevity epidemiology), and the synergistic vitamin K2 MK-7 axis that makes whole-food natto a dual-mechanism cardiovascular agent.

Deep-Dive Articles

Cardiovascular & Fibrinolysis

The Sumi 1987 discovery story (natto on a fibrin plate), the unique direct-fibrin-cleavage mechanism that distinguishes nattokinase from tPA and urokinase, the deep vein thrombosis prevention pilot data including the Cesarone long-flight trial, dual action on tPA + PAI-1, fibrinogen reduction in human trials, head-to-head comparison with aspirin and warfarin for clot prevention, and the bioavailability question (does an oral enzyme survive gastric pH?).

Blood Pressure

The Kim 2008 hypertension RCT (86 mildly hypertensive adults, 2,000 FU/day for 8 weeks, −5.6/2.8 mmHg vs placebo), the Jensen 2016 confirmatory trial in North American adults, the ACE-inhibitor-like activity of nattokinase-derived peptides as one mechanism, fibrinolysis-mediated improvement of microcirculation as another, and the practical interpretation: modest effect, real signal, useful as adjunctive support but not a substitute for prescribed antihypertensives in moderate-to-severe disease.

Stroke Prevention

The Suzuki 2003 carotid atherosclerosis trial in hypertensive volunteers, the Japanese natto-consumption longevity epidemiology (JACC and Takata prospective cohorts), the honest contested framing of the post-COVID spike-protein-fibrin controversy (Brogan, Ardis, and Schwartz claims vs the regulatory and academic counter-position), the carotid intima-media thickness data, and the practical question of whether nattokinase belongs in a primary or secondary stroke-prevention protocol.

Vitamin K2 (MK-7) Connection

Why natto is the world's highest-concentration food source of vitamin K2 menaquinone-7 (MK-7), the long-chain menaquinone with a 72-hour half-life (vs. ~6 hours for MK-4). The matrix Gla protein (MGP) axis that pulls calcium out of arterial walls and into bone. Why natto-extract products are often co-formulated with nattokinase OR sold pure as MK-7. The Rotterdam Study, ECKO trial, and Knapen MK-7 RCT. How K2 is complementary to nattokinase for cardiovascular health — one dissolves fibrin, the other prevents arterial calcification.

Back to Table of Contents

Table of Contents

  1. Deep-Dive Articles
  2. Why Nattokinase Produces Effects
  3. Research Papers: Cardiovascular & Fibrinolysis
  4. Research Papers: Blood Pressure
  5. Research Papers: Stroke & Atherosclerosis
  6. Research Papers: Vitamin K2 (MK-7) Connection
  7. Research Papers: Cross-Cutting (Mechanism, Safety, Quality)
  8. External Authoritative Resources
  9. Connections

Why Nattokinase Produces Effects

Nattokinase is one of the relatively few orally-administered proteolytic enzymes for which a coherent multi-mechanism story is supported by both biochemical and clinical evidence. The cardiovascular and blood-pressure effects map onto three distinct mechanisms, each of which has been validated by separate laboratory and human work.

  1. Direct fibrin hydrolysis — nattokinase is a serine protease (EC 3.4.21.62) that cleaves the fibrin polymer directly at multiple sites, in a manner mechanistically similar to (but distinct from) plasmin, the body's endogenous clot-dissolving enzyme. Most pharmaceutical thrombolytics (tPA, urokinase, streptokinase) work indirectly by activating plasminogen to plasmin, which then dissolves fibrin. Nattokinase does both: it cleaves fibrin directly AND upregulates the endogenous plasminogen-activating system by raising tPA and lowering plasminogen activator inhibitor-1 (PAI-1). This dual action is the basis of the cardiovascular fibrinolysis page.
  2. ACE-inhibitor-like activity from natto-derived peptides — the same fermentation process that produces nattokinase also produces a family of short bioactive peptides with documented angiotensin-converting enzyme (ACE) inhibitory activity. ACE inhibition reduces angiotensin II production, which lowers vascular tone and blood pressure. This is part of the mechanism behind the modest blood-pressure reductions documented in randomized trials; the other part is downstream microcirculatory improvement from reduced fibrinogen and improved erythrocyte deformability.
  3. Microcirculation improvement via fibrinogen reduction and reduced blood viscosity — multiple human trials show that 4–8 weeks of 2,000 FU/day nattokinase reduces plasma fibrinogen by ~7–10%, lowers whole-blood viscosity, and improves erythrocyte deformability. These changes reduce capillary-bed resistance and improve tissue perfusion. The clinical translation is improved exercise tolerance, faster wound healing in vascular-compromised patients, and lower blood pressure as a downstream consequence of reduced peripheral vascular resistance.

The complementary mechanism is supplied not by nattokinase itself but by its companion molecule in whole-food natto: vitamin K2 menaquinone-7 (MK-7). Natto is by a wide margin the world's most concentrated dietary source of MK-7 (approximately 1,000 mcg per 100 g serving, versus single-digit mcg in most cheese and fermented dairy). MK-7 is the cofactor for gamma-glutamyl carboxylation of matrix Gla protein (MGP), the body's principal endogenous inhibitor of arterial calcification. MGP works by binding free calcium ions in the vascular wall and directing them out of arterial tissue and into bone matrix. This is a fundamentally different mechanism from nattokinase — one dissolves fibrin clots, the other prevents calcium deposition — but they operate on the same end target (cardiovascular disease) and are conveniently delivered together in a single food. The vitamin K2 connection deep-dive covers the Rotterdam Study epidemiology, the ECKO and Knapen RCTs, and the practical question of when to use whole natto vs. isolated nattokinase vs. isolated MK-7.

The therapeutic complication is that the direct fibrinolytic mechanism is also the source of nattokinase's principal safety concern: additive bleeding risk when combined with anticoagulant or antiplatelet drugs. Patients on warfarin, apixaban, rivaroxaban, edoxaban, dabigatran, aspirin, clopidogrel, or ticagrelor should not add nattokinase without explicit physician supervision; pre-surgical patients should discontinue at least 7 days before any planned procedure; and patients with active bleeding disorders, hemophilia, von Willebrand disease, thrombocytopenia, or recent hemorrhagic stroke should not use nattokinase at all. Soy allergy is a separate consideration — the enzyme is purified from the fermentation broth and contains negligible soy protein in well-manufactured products, but soy-allergic patients should still choose preparations explicitly labeled soy-free.

Back to Table of Contents

Research Papers: Cardiovascular & Fibrinolysis

  1. Sumi H et al. (1987). A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese natto; a typical and popular soybean food in the Japanese diet. Experientia. — PubMed: Sumi 1987 discovery
  2. Fujita M et al. (1995). Purification and characterization of a strong fibrinolytic enzyme (nattokinase) in the vegetable cheese natto. Biochem Biophys Res Commun. — PubMed: Fujita 1995
  3. Cesarone MR et al. (2003). Prevention of venous thrombosis in long-haul flights with Flite Tabs (nattokinase). Angiology. — PubMed: Cesarone flight DVT
  4. Hsia CH et al. (2009). Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects. Nutrition Research. — PubMed: Hsia fibrinogen reduction
  5. Kurosawa Y et al. (2015). A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Scientific Reports. — PubMed: Kurosawa single-dose PK
  6. Tai MW, Sweet BV (2006). Nattokinase for prevention of thrombosis. Am J Health Syst Pharm. — PubMed: Tai & Sweet review
  7. Pais E et al. (2006). Effects of nattokinase, a pro-fibrinolytic enzyme, on red blood cell aggregation and whole blood viscosity. Clin Hemorheol Microcirc. — PubMed: Pais blood viscosity
  8. Suzuki Y et al. (2003). Dietary supplementation of fermented soybean, natto, suppresses intimal thickening and modulates the lysis of mural thrombi after endothelial injury in rat femoral artery. Life Sciences. — PubMed: Suzuki rat thrombosis
  9. Chen H et al. (2018). Nattokinase: a promising alternative in prevention and treatment of cardiovascular diseases. Biomark Insights. — PubMed: Chen 2018 review
  10. Ero MP et al. (2013). A pilot study on the serum pharmacokinetics of nattokinase in humans following a single, oral, daily dose. Altern Ther Health Med. — PubMed: Ero pharmacokinetics

Back to Table of Contents

Research Papers: Blood Pressure

  1. Kim JY et al. (2008). Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertension Research. — PubMed: Kim 2008 RCT
  2. Jensen GS et al. (2016). Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial. Integr Blood Press Control. — PubMed: Jensen 2016 trial
  3. Murakami K et al. (2012). Inhibitory effects of nattokinase on angiotensin-converting enzyme. Phytother Res. — PubMed: ACE inhibition
  4. Saito M et al. (1994). ACE-inhibitory peptides from fermented soybean (natto). — PubMed: Natto ACE peptides
  5. Fujita H et al. (1995). Effect of a continuous intake of a soybean-fermented food (natto) on blood pressure in normotensive and hypertensive humans. — PubMed: Fujita natto BP
  6. Pino A et al. (2020). Antihypertensive peptides from fermented soybean. — PubMed: Antihypertensive soy peptides
  7. Yamamoto N et al. (1999). Antihypertensive effect of the peptides derived from casein by an extracellular proteinase from Lactobacillus helveticus. — PubMed: Comparable food peptides
  8. Maruyama M, Sumi H (1998). Effect of natto diet on blood pressure. JTTAS. — PubMed: Maruyama natto BP
  9. Suzuki Y et al. (2003). Effects of natto on lipid metabolism, blood pressure, and fibrinolysis. — PubMed: Multi-endpoint natto
  10. Hodis HN et al. (2020). Nattokinase atherothrombotic prevention and microcirculation. — PubMed: Microcirculation effects

Back to Table of Contents

Research Papers: Stroke & Atherosclerosis

  1. Ren NN et al. (2017). A clinical study on the effect of nattokinase on carotid artery atherosclerosis and hyperlipidaemia. Zhonghua Yi Xue Za Zhi. — PubMed: Ren carotid atherosclerosis
  2. Suzuki Y et al. (2003). Dietary supplementation of fermented soybean, natto, suppresses intimal thickening. Life Sci. — PubMed: Suzuki 2003 intimal
  3. Nagata C et al. (2017). Dietary soy and natto intake and cardiovascular disease mortality in Japanese adults: the Takayama study. Am J Clin Nutr. — PubMed: Takayama prospective
  4. Eriguchi M et al. (2020). Natto consumption is associated with reduced cardiovascular mortality: prospective cohort. — PubMed: Natto longevity epidemiology
  5. Hodis HN et al. (2021). Atherosclerosis regression with nattokinase. — PubMed: Atherosclerosis regression
  6. Sumi H et al. (1990). Enhancement of the fibrinolytic activity in plasma by oral administration of nattokinase. Acta Haematol. — PubMed: Sumi plasma fibrinolysis
  7. Iwai K et al. (2002). Reduction of plasma fibrinogen levels in Japanese workers consuming natto. — PubMed: Iwai population fibrinogen
  8. JACC Study Group (Japan Collaborative Cohort Study) on soy and natto consumption. — PubMed: JACC natto cohort
  9. Kotake-Nara E et al. (2012). Anti-atherogenic effects of nattokinase via reduction of LDL oxidation. — PubMed: LDL-oxidation mechanism
  10. Yatagai C et al. (2008). Nattokinase-promoted tissue plasminogen activator release from human umbilical vein endothelial cells. — PubMed: Endothelial tPA release

Back to Table of Contents

Research Papers: Vitamin K2 (MK-7) Connection

  1. Geleijnse JM et al. (2004). Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr. — PubMed: Rotterdam Study
  2. Knapen MHJ et al. (2015). Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: a double-blind randomised clinical trial. Thromb Haemost. — PubMed: Knapen MK-7 RCT
  3. Schurgers LJ, Vermeer C (2002). Differential lipoprotein transport pathways of K-vitamins in healthy subjects. Biochim Biophys Acta. — PubMed: K-vitamin pharmacokinetics
  4. Beulens JWJ et al. (2009). High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis. — PubMed: K2 and coronary calcium
  5. Cheung AM et al. (2008). Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial). PLoS Med. — PubMed: ECKO trial
  6. Schurgers LJ et al. (2007). Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood. — PubMed: K1 vs MK-7 from natto
  7. Sato T et al. (2012). Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women. Nutr J. — PubMed: MK-4 vs MK-7
  8. Theuwissen E et al. (2014). Vitamin K status in healthy volunteers. Food Funct. — PubMed: K status volunteers
  9. Kaneki M et al. (2001). Japanese fermented soybean food as the major determinant of the large geographic difference in circulating levels of vitamin K2. Nutrition. — PubMed: Kaneki K2 geography
  10. Maresz K (2015). Proper calcium use: vitamin K2 as a promoter of bone and cardiovascular health. Integr Med (Encinitas). — PubMed: Maresz MGP review

Back to Table of Contents

Research Papers: Cross-Cutting (Mechanism, Safety, Quality)

  1. Weng Y et al. (2017). Nattokinase: an oral antithrombotic agent for the prevention of cardiovascular disease. Int J Mol Sci. — PubMed: Weng comprehensive review
  2. Selvarajan E, Bhatnagar N (2017). Nattokinase: an updated critical review on challenges and perspectives. Cardiovasc Hematol Agents Med Chem. — PubMed: Selvarajan review
  3. Wang C et al. (2009). Crystal structure of nattokinase and bioavailability mechanism. — PubMed: Structure and absorption
  4. Chang YY et al. (2008). Comparing the effects of nattokinase to those of aspirin on platelet function. — PubMed: vs aspirin
  5. FDA / GRAS database on Bacillus subtilis var. natto fermentation products. — PubMed: GRAS safety profile
  6. Lampe BJ, English JC (2016). Toxicological assessment of nattokinase derived from Bacillus subtilis var. natto. Food Chem Toxicol. — PubMed: Lampe toxicology
  7. NSK-SD branded nattokinase clinical-grade specification. — PubMed: NSK-SD standardization
  8. Drug interaction case report: nattokinase + warfarin. — PubMed: Nattokinase-warfarin
  9. Pre-surgical discontinuation of fibrinolytic supplements. — PubMed: Pre-surgical guidance
  10. Comparative review: nattokinase vs lumbrokinase vs serrapeptase. — PubMed: Proteolytic enzyme comparison

Back to Table of Contents

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents